| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Carl Anthony Evans last filed a Form 4 in April 2024, as Director at CNSP. Carl Anthony Evans's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 33,458 shares of CNSP. Net of sales, the CNSP filings show accumulation of 33,333 shares.
Carl Anthony Evans has 6 Form 4 filings on record from June 2020 to April 2024, all as Director at CNS Pharmaceuticals (CNSP), 2020–2024.
The 9 reported transactions were 7 option or other derivative awards, 1 open-market purchase and 1 stock award.
Counted by filing, the open-market trades come to 1 purchase worth about $10K and no sales.
The only open-market purchase was 33,333 shares of CNSP at an average $0.30 on February 1, 2024, about $10K. Twelve months later CNSP was down 99%.
Shares as reported in the last Form 4 for each company; the most recent is from April 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 1, 2024 | CNSP Cns Pharmaceuticals, Inc. | Director | Buy | 33,333 | $0.30 | $9,999.90 | +26,666% | -13.7% | -99.2% |